Nanobiotix SA

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months

04 Oct 2023 15:30:02 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

29 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

28 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

26 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

19 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

05 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

31 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

15 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

04 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

20 Jul 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

19 Jul 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

10 Jul 2023 01:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

08 Jun 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

17 May 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

05 May 2023 00:30:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

24 Apr 2023 18:33:54 By Nasdaq GlobeNewswire

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

17 Apr 2023 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Apr 2023 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

27 Mar 2023 15:15:00 By Nasdaq GlobeNewswire